Merriam Report archives offer solid evidence to the effective and predictive capabilities of the MR research and analysis.  
        Click any company below to view a full report.             
An Enviable Track Record   
The Merriam Report boasts a remarkable performance and accuracy rate*  
"Undervalued" stocks generated an average 25.95% profit (a 93% accuracy rate)
"
Overvalued" stocks declined an average -34.14% (a 92% accuracy rate)
*Based on returns generated 3-6 months following date of report for all back-tested and actual investments 1997- June 30, 2010
"The proof is in the pudding"
MR Quarterly Newsletter Updates
Winter 2010: Major Diversified Chemicals
Our in-depth analysis of the deeply cyclical chemical industry
identified
Eastman Chemical (EMN) as a company with
improving earnings quality.

At time of newsletter publication (mid-Jan.), EMN shares
were trading at $60.  In
Summary Analysis, we advised
readers to consider taking positions in EMN on any pull-back
to the mid $50 area.  












On April 22nd, the company reported stellar Q1 results,
blowing consensus estimates right out of the water!

Subscribers of the
Merriam Report Quarterly who heeded
our actionable research and analysis, made a potential 25%
profit on EMN as compared to a 14% gain in the S&P 500
(Jan. 29 through April 23).

              Newsletter Archives
Spring 2008: A Look at the Drug Stocks
Fall 2008: Consumer Staples & Household Products
Report Date
Company & Ticker
MR Rating
Share Price as of
Report Date
Share Price as of
Next Earnings
Announcement
Results
5-31-10
Cytec Industries (CYT)
 Undervalued   
$40.87
$49.86
+ 21.99%
2-28-08
Zoltek (ZOLT)
Overvalued
$22.88
$12.70
- 44.49%
9-20-08
Nike (NKE)
Overvalued
$63.70
$53.08
- 16.67%
10-28-09
Target Corp (TGT)
Overvalued
$48.24
$45.30
- 6.09%
5-26-09
Psychiatric Solutions (PSYS)
Undervalued
$18.88
$24.98
+ 32.30%
6-12-09
Cintas Corp. (CTAS)
Undervalued
 
 
+ 22%
9-21-09
Eastman Kodak (EK)
Overvalued
$5.36
$3.47
- 35.26%
10-06-09
Allegheny Technologies (ATI)
Overvalued
$35.24
$29.70
- 15.72%
"MR Rating" is based on our interpretation of the data presented and is provided for informational purposes only.  "Results" show changes in
the price of a security between the date of report and the subsequent earnings release date.  
Merriam Report  Investment Research Archives
Updated on 7-23-10
NEW